Vilya

Vilya is a biotechnology company focusing on developing precision medicine to target selective proteins. The company uses its machine learning-powered proprietary platform to create novel artificial molecules with tailored drug-like properties that can target difficult-to-drug therapeutic targets across a wide range of indications (such as covid and cancer). 

The company planned to license out the platform and molecules. The molecular structure will range in size between small molecules and antibodies with drug-like properties such as the ability to cross biological membranes and disrupt protein-protein interactions. The company’s platform gives it the ability to design membrane permeable molecules with high structural accuracy that has given way to a new class of medicines. 

Vilya was created out of research at the Institute of Protein Design led by David Baker, Ph.D., to use computational design to the class of drugs. 

Funding and Financials

The company launched out of stealth in August 2022 and raised USD 50 million in a Series A funding round led by ARCH Venture Partners. The new funds were used to develop new drugs, using the company’s platform.